NCT05567068CompletedPhase 2
Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis
Repurposing Atorvastatin in Patients With Ulcerative Colitis Treated With Mesalamine by Modulation of mTOR/NLRP3 Pathway.
Source: ClinicalTrials.gov · Last updated 18 Nov 2025
Brief summary (registry, in English)
Statins exert numerous pleiotropic effects including anti-inflammatory, antioxidant properties, endothelial function improvement, and immunomodulation independent of their basic lipid-lowering properties.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 54 (actual)
- First submitted
- 1 Oct 2022
- Start date
- 1 Feb 2023
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Tanta University
- Diseases
- Ulcerative colitis
- NCT number
- NCT05567068
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 54
- From 1 Feb 2023 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients taking rectal or systemic steroids
- Patients taking immunosuppressives or biological therapies
Other illness
- Colorectal cancer patients
Other
- Breastfeeding
- Significant liver and kidney function abnormalities
- Patients with severe UC
Who the study is looking for
- Age ≥ 18 years
- Both males and females will be included
- Negative pregnancy test and effective contraception.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine, Mansoura University Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
Related publications
- Atorvastatin as an immunomodulatory adjunct in ulcerative colitis, beyond lipid lowering to inflammation control: a randomized controlled pilot study.Front Pharmacol · 2025 · PMID 41235106
This page is information, not medical advice. Discuss any trial with your doctor.